For clinical trials among children, the vaccine was administered at a dosage 10 times less than in adults. The drug was administered in the standard mode – in two doses with an interval of 21 days. It turned out that this is not enough for the subjects to develop a sufficient immune response.
Children who were vaccinated had blood tests taken. Scientists hoped to get the same parameters of immune protection as in people aged 16-25. Such indicators came out in infants from six months to two years, but in children from two to five years, they did not receive the necessary immune response.
The researchers now want to try giving children a third dose of the vaccine. The test results will be announced in early 2022.
Download Link
